Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
615 stopped studies mapped to Melanoma and descendants · 90% state a reason
Over the 615 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02306512 | Mohs and Immunofluorescence for Malignant Melanoma In Situ | N/A | withdrawn | Dec 3, 2014 | University of Miami | PI is leaving the University of Miami | Other (stated, no rule matched) |
| NCT02050321 | A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma | Phase 2 | terminated | Jan 30, 2014 | University of Arizona | Pharmaceutical company pulled support for the trial. | Sponsor / business decision |
| NCT00929019 | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk… | Phase 1 / Phase 2 | terminated | Jun 26, 2009 | Radboud University Medical Center | slow accrual | Enrollment / accrual |
| NCT02327390 | Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma | Phase 1 | terminated | Dec 30, 2014 | Case Comprehensive Cancer Center | PI Left | Investigator |
| NCT00540969 | Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone… | Phase 3 | terminated | Oct 8, 2007 | Alliance for Clinical Trials in Oncology | Low accrual | Enrollment / accrual |
| NCT03177941 | Teaching Skin Self-Examination to First-degree Relatives of Melanoma Patients Using… | N/A | withdrawn | Jun 6, 2017 | Northwestern University | The company decided not to enroll subjects. The app was never developed. | Enrollment / accrual |
| NCT00791271 | Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion | Phase 1 | terminated | Nov 14, 2008 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01814046 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular… | Phase 2 | terminated | Mar 19, 2013 | National Cancer Institute (NCI) | Investigator left the National Institutes of Health (NIH) | Investigator |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus… | Phase 2 | withdrawn | May 5, 2016 | Bristol-Myers Squibb | Insufficient enrollment | Enrollment / accrual |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in… | Phase 2 | withdrawn | Jul 18, 2017 | National Cancer Institute (NCI) | The study was never approved by CTEP neither was it ever activated | Other (stated, no rule matched) |
| NCT01876641 | Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus…(ML28604) | Phase 1 | terminated | Jun 12, 2013 | Mohammed M Milhem | Loss of funding | Funding |
| NCT02447939 | Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and… | Phase 1 | withdrawn | May 19, 2015 | GlaxoSmithKline | Change in strategy | Sponsor / business decision |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer,… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT00961376 | Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear… | Phase 2 | terminated | Aug 19, 2009 | Providence Health & Services | PI Discretion | Other (stated, no rule matched) |
| NCT01636960 | A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese… | Phase 1 | terminated | Jul 10, 2012 | Merck Sharp & Dohme LLC | The study was terminated after 118 weeks from the study start, during the maintenance phase, due to… | Other (stated, no rule matched) |
| NCT03297463 | Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic… | Phase 1 / Phase 2 | withdrawn | Sep 29, 2017 | Masonic Cancer Center, University of Minnesota | Replaced by another study. | Other (stated, no rule matched) |
| NCT03073473 | Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers | — | terminated | Mar 8, 2017 | Cota Inc. | Poor accrual | Enrollment / accrual |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced… | Phase 1 / Phase 2 | withdrawn | Oct 31, 2017 | National Cancer Institute (NCI) | The study itself was Disapproved on 04/20/2018 and will not be moving forward. | Other (stated, no rule matched) |
| NCT01006252 | A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma(SUMMIT-1) | Phase 3 | terminated | Nov 2, 2009 | Eli Lilly and Company | More possibly treatment-related deaths on tasisulam-sodium arm. | Other (stated, no rule matched) |
| NCT02507947 | SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access | — | withdrawn | Jul 24, 2015 | European Organisation for Research and Treatment of Cancer - EORTC | Study closed | Other (stated, no rule matched) |
| NCT01341496 | Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal | Phase 1 | terminated | Apr 25, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02839694 | Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People… | Phase 1 | withdrawn | Jul 21, 2016 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02113683 | Validation of MMS Test for Cancer Monitoring(MMS-TM) | — | terminated | Apr 15, 2014 | MedInnovation GmbH | insufficient recruitment on the part of clinic; study will not resume | Enrollment / accrual |
| NCT01453361 | Phase II FANG™ in Advanced Melanoma | Phase 2 | terminated | Oct 17, 2011 | Gradalis, Inc. | Business Decision to pursue other indications | Sponsor / business decision |
| NCT02915666 | A Clinical Trial of Patients With Melanoma | Phase 1 | withdrawn | Sep 27, 2016 | University of Texas Southwestern Medical Center | No subjects consented for enrollment on this study. | Enrollment / accrual |
| NCT01533948 | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by… | Phase 2 | terminated | Feb 16, 2012 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT03282188 | REO13 Melanoma With of Without GM-CSF | Phase 1 / Phase 2 | withdrawn | Sep 13, 2017 | University of Leeds | Withdrawn by Sponsor | Other (stated, no rule matched) |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Phase 1 | terminated | Sep 7, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT02796352 | A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV… | Phase 2 | terminated | Jun 10, 2016 | Ahmad Tarhini | Slow accrual. | Enrollment / accrual |
| NCT03205722 | The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced… | — | withdrawn | Jul 2, 2017 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT01702896 | Interleukin-2 in Metastatic Melanoma | Phase 2 | terminated | Oct 10, 2012 | Western Regional Medical Center | PI Decision | Other (stated, no rule matched) |
| NCT02812693 | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With… | Phase 1 / Phase 2 | withdrawn | Jun 24, 2016 | Joanne Jeter | poor accrual | Enrollment / accrual |
| NCT01543464 | Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients | Phase 2 | terminated | Mar 5, 2012 | Inge Marie Svane | Diminished rectruitment | Other (stated, no rule matched) |
| NCT01689974 | Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic… | Phase 2 | terminated | Sep 21, 2012 | NYU Langone Health | Study terminated because PI left institution. Planned Statistical analysis not available | Investigator |
| NCT00588263 | Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish… | — | withdrawn | Jan 8, 2008 | Memorial Sloan Kettering Cancer Center | Data from MSK-IMPACT is sufficient for relevant analyses going forward | Other (stated, no rule matched) |
| NCT01264874 | MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients(MelaViD) | Phase 3 | terminated | Dec 22, 2010 | European Institute of Oncology | poor accrual rate | Enrollment / accrual |
| NCT01721603 | Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets | Phase 2 | terminated | Nov 6, 2012 | University of California, San Francisco | Low accrual | Enrollment / accrual |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | Phase 2 | terminated | Nov 15, 2013 | Nina Bhardwaj | PI discretion, low enrollment | Enrollment / accrual |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone… | Phase 1 / Phase 2 | withdrawn | Oct 9, 2008 | Masonic Cancer Center, University of Minnesota | No patient accrual. | Enrollment / accrual |
| NCT01328106 | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | Phase 2 | withdrawn | Apr 4, 2011 | GlaxoSmithKline | The study was cancelled by the sponsor prior to initiation of study enrollment. No subjects were… | Enrollment / accrual |
| NCT01740401 | CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma | Phase 2 | terminated | Dec 4, 2012 | Icahn School of Medicine at Mount Sinai | Primary Endpoint not met | Other (stated, no rule matched) |
| NCT02719015 | Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral… | Phase 1 / Phase 2 | withdrawn | Mar 24, 2016 | M.D. Anderson Cancer Center | No IND Serial # | Other (stated, no rule matched) |
| NCT01495988 | Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV… | Phase 2 | terminated | Dec 21, 2011 | Melanoma Research Foundation Breakthrough Consortium | Slow accrual; toxicity; change in priorities | Safety / toxicity |
| NCT01009515 | Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma | Phase 2 | terminated | Nov 6, 2009 | New Mexico Cancer Research Alliance | Low accrual; target accrual not met | Enrollment / accrual |
| NCT02736123 | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | Phase 1 / Phase 2 | withdrawn | Apr 13, 2016 | University of Pittsburgh | PI is closing the trial as he will be leaving the University of Pittsburgh Medical Center | Other (stated, no rule matched) |
| NCT02111863 | Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With… | Phase 2 | terminated | Apr 11, 2014 | National Cancer Institute (NCI) | Study terminated due to low accrual and change in research focus. | Enrollment / accrual |
| NCT01696045 | Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With… | Phase 2 | terminated | Sep 28, 2012 | Bristol-Myers Squibb | Slow accrual | Enrollment / accrual |
| NCT01833767 | Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma | Phase 2 | withdrawn | Apr 17, 2013 | Western Regional Medical Center | No participants enrolled | Enrollment / accrual |
| NCT01138410 | Study of a DNA Immunotherapy to Treat Melanoma | Phase 1 / Phase 2 | terminated | Jun 7, 2010 | Scancell Ltd | Product availability | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 7, 2019source: clinicaltrials